AP NEWS

Dyskinesia - Pipeline Review, H2 2018 - ResearchAndMarkets.com

September 14, 2018

DUBLIN--(BUSINESS WIRE)--Sep 14, 2018--The “Dyskinesia - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Dyskinesia - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Dyskinesia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dyskinesia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 16, 4, 17, 6 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Dyskinesia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered

Introduction Dyskinesia - Overview Dyskinesia - Therapeutics Development Dyskinesia - Therapeutics Assessment Dyskinesia - Companies Involved in Therapeutics Development Dyskinesia - Drug Profiles Dyskinesia - Dormant Projects Dyskinesia - Discontinued Products Dyskinesia - Product Development Milestones

Companies Featured

Addex Therapeutics Ltd Advicenne SA Amarantus Bioscience Holdings Inc Avanir Pharmaceuticals Inc Cadent Therapeutics Cavion LLC Cerevance Inc Clevexel Pharma SAS DanPET AB EpiVax Inc H. Lundbeck AS Heptares Therapeutics Ltd India Globalization Capital Inc Ipsen SA IRLAB Therapeutics AB Medy-Tox Inc Merz Pharma GmbH & Co KgaA Mylan NV Neurim Pharmaceuticals Ltd Neurocrine Biosciences Inc Neurolixis Inc Newron Pharmaceuticals SpA Phenomenome Discoveries Inc Revance Therapeutics Inc Sage Therapeutics Inc SOM Biotech SL Ultragenyx Pharmaceutical Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/34ztqt/dyskinesia?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180914005382/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/14/2018 11:30 AM/DISC: 09/14/2018 11:30 AM

http://www.businesswire.com/news/home/20180914005382/en

AP RADIO
Update hourly